Denali Advisors LLC Trims Stake in G1 Therapeutics, Inc. (NASDAQ:GTHX)

Denali Advisors LLC cut its holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX) by 29.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 86,100 shares of the company’s stock after selling 35,700 shares during the period. Denali Advisors LLC owned 0.16% of G1 Therapeutics worth $372,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Creative Financial Designs Inc. ADV raised its holdings in G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after purchasing an additional 17,475 shares during the period. Jump Financial LLC purchased a new position in shares of G1 Therapeutics during the 4th quarter valued at about $105,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of G1 Therapeutics by 68.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock valued at $294,000 after buying an additional 82,879 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of G1 Therapeutics during the 3rd quarter valued at approximately $189,000. Finally, abrdn plc purchased a new stake in G1 Therapeutics in the 4th quarter worth approximately $1,293,000. Hedge funds and other institutional investors own 24.21% of the company’s stock.

G1 Therapeutics Price Performance

Shares of GTHX opened at $2.57 on Thursday. G1 Therapeutics, Inc. has a 1 year low of $1.08 and a 1 year high of $6.14. The company has a 50 day simple moving average of $3.50 and a two-hundred day simple moving average of $3.56. The company has a quick ratio of 2.55, a current ratio of 2.94 and a debt-to-equity ratio of 1.34.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $14.48 million for the quarter, compared to analysts’ expectations of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. During the same period in the previous year, the business posted ($0.53) earnings per share. Sell-side analysts anticipate that G1 Therapeutics, Inc. will post -0.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on GTHX. Wedbush reiterated an “outperform” rating and issued a $3.00 price target (down from $5.00) on shares of G1 Therapeutics in a research report on Monday, June 24th. HC Wainwright dropped their target price on shares of G1 Therapeutics from $9.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, June 25th. Finally, Needham & Company LLC decreased their price target on G1 Therapeutics from $12.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, June 25th.

G1 Therapeutics Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.